April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
The Role of the Different VEGF-Isoforms in Scar Formation After Glaucoma Filtration Surgery
Author Affiliations & Notes
  • T. Van Bergen
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • E. Vandewalle
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • S. Van de Veire
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
  • L. Moons
    Department of Biology,
    KU Leuven, Leuven, Belgium
  • I. Stalmans
    Lab of Ophthalmology,
    KU Leuven, Leuven, Belgium
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Van Bergen, E. Vandewalle, S. Van de Veire, L. Moons, I. Stalmans; The Role of the Different VEGF-Isoforms in Scar Formation After Glaucoma Filtration Surgery. Invest. Ophthalmol. Vis. Sci. 2010;51(13):602.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We previously showed that in vitro pegaptanib (MacugenTM, Pfizer) addition inhibited endothelial cells (HUVEC) in a dose-dependent way, whereas human Tenon fibroblasts (HTF) were only inhibited at the highest dose. Bevacizumab, on the other hand, was able to inhibit both HUVEC and HTF dose-dependently. In a rabbit model of trabeculectomy, a single injection of bevacizumab was able to reduce angiogenesis as well as fibrosis. A single pegaptanib injection only temporarily improved the surgical outcome by reducing angiogenesis, without effecting inflammation and fibrosis. Therefore, we checked whether repeated injections of pegaptanib can more efficiently improve the surgical outcome. Also, we aimed at further elucidating the role of the different VEGF-isoforms on the process of wound healing in vivo and in vitro.

Methods: : The effect of the different VEGF-isoforms (VEGF121 & VEGF165 (R&D Systems), and VEGF189 (Cell Sciences)) on HUVEC and HTF in vitro was determined by a WST-1 assay. In a group of 12 rabbits, injections (0,3mg; 90 µl) were given every 2 days subconjunctivally until day 14. The outcome of the treatment was investigated 15 and 30 days after surgery by analysis of angiogenesis (CD31), inflammation (CD45) and fibrosis (Sirius Red).

Results: : In vitro

Conclusions: : Addition of VEGF121 and VEGF165 stimulated HUVEC proliferation, while VEGF121 and VEGF189 increased the growth of HTF in vitro. Repeated injections of pegaptanib improved surgery outcome by reducing angiogenesis on day 15 and 30 after surgery, however no differences were visible in inflammation and fibrosis. These data indicate that VEGF-isoforms play a differential role in ocular wound healing. VEGF165 may affect blood vessels, whereas the other isoforms may be more important in inflammation and fibrosis.

Keywords: vascular endothelial growth factor • wound healing 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.